Lucid Diagnostics
LUCD
116 hedge funds and large institutions have $65.7M invested in Lucid Diagnostics in 2026 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 59 increasing their positions, 13 reducing their positions, and 10 closing their positions.
354% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 13
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
60% more capital invested
Capital invested by funds: $41M → $65.7M (+$24.7M)
13% more funds holding
Funds holding: 103 → 116 (+13)
10.11% more ownership
Funds ownership: 20.13% → 30.24% (+10%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $694K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$9.55M |
| 2 |
BlackRock
New York
|
+$4.03M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
+$3.23M |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$2.59M |
| 5 |
First Manhattan
New York
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$462K |
| 2 |
Goldman Sachs
New York
|
-$185K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$137K |
| 4 |
Squarepoint
New York
|
-$132K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$125K |
LUCD Hedge Fund Activity: Q2 2026 in Review
116 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Lucid Diagnostics (LUCD) for Q2 2026, worth a combined $65.7M — up 60% from $41M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LUCD positions and 10 closed out — a net gain of 15 holders — while 59 added to existing stakes and 13 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $9.55M. The largest seller was Renaissance Technologies, cutting an estimated $462K.
- 116 institutional investors held Lucid Diagnostics (LUCD) as of Q2 2026, up from 103 in Q1 2026.
- Funds reported $65.7M of Lucid Diagnostics stock for Q2 2026, up 60% quarter-over-quarter.
- 25 funds opened new Lucid Diagnostics positions in Q2 2026 and 10 closed out, a net change of +15 holders.
- The largest Lucid Diagnostics buyer in Q2 2026 was Alyeska Investment Group, an estimated $9.55M added.
- The largest Lucid Diagnostics seller in Q2 2026 was Renaissance Technologies, an estimated $462K sold.
Based on aggregated 13F filings for Q2 2026.